| __timestamp | Alnylam Pharmaceuticals, Inc. | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 190249000 | 45967000 |
| Thursday, January 1, 2015 | 276495000 | 114737000 |
| Friday, January 1, 2016 | 382392000 | 183204000 |
| Sunday, January 1, 2017 | 390635000 | 231644000 |
| Monday, January 1, 2018 | 505420000 | 293998000 |
| Tuesday, January 1, 2019 | 655114000 | 357355000 |
| Wednesday, January 1, 2020 | 654819000 | 412084000 |
| Friday, January 1, 2021 | 792156000 | 497153000 |
| Saturday, January 1, 2022 | 883015000 | 705789000 |
| Sunday, January 1, 2023 | 1004415000 | 648449000 |
| Monday, January 1, 2024 | 1126232000 |
Infusing magic into the data realm
In the ever-evolving landscape of biopharmaceuticals, research and development (R&D) spending is a critical indicator of innovation and future growth. Alnylam Pharmaceuticals, Inc. and Ultragenyx Pharmaceutical Inc. have been at the forefront of this trend, showcasing significant investment in R&D over the past decade.
Since 2014, Alnylam has consistently increased its R&D budget, with a remarkable 428% growth by 2023. This commitment underscores their dedication to pioneering RNA interference therapeutics.
Ultragenyx, focusing on rare and ultra-rare diseases, has also shown a robust R&D growth of approximately 1,310% from 2014 to 2022, peaking in 2022. This reflects their strategic focus on expanding their therapeutic pipeline.
These trends highlight the dynamic nature of the biopharmaceutical industry, where strategic R&D investments are pivotal for long-term success.
Research and Development Expenses Breakdown: Regeneron Pharmaceuticals, Inc. vs Alnylam Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Alnylam Pharmaceuticals, Inc. and United Therapeutics Corporation
R&D Insights: How Alnylam Pharmaceuticals, Inc. and Intra-Cellular Therapies, Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Alnylam Pharmaceuticals, Inc. and Incyte Corporation
Research and Development: Comparing Key Metrics for Alnylam Pharmaceuticals, Inc. and Exelixis, Inc.
Comparing Innovation Spending: Alnylam Pharmaceuticals, Inc. and Opthea Limited
R&D Spending Showdown: Alnylam Pharmaceuticals, Inc. vs Amneal Pharmaceuticals, Inc.
Comparing Innovation Spending: Alnylam Pharmaceuticals, Inc. and Xencor, Inc.
Research and Development Investment: Intra-Cellular Therapies, Inc. vs Ultragenyx Pharmaceutical Inc.
Analyzing R&D Budgets: Alkermes plc vs Ultragenyx Pharmaceutical Inc.
Who Prioritizes Innovation? R&D Spending Compared for Ultragenyx Pharmaceutical Inc. and PTC Therapeutics, Inc.
Comparing Innovation Spending: Ultragenyx Pharmaceutical Inc. and Travere Therapeutics, Inc.